Liraglutide accelerated diabetic wound healing in mice by directly binding to the Myo1c protein and activating the Myo1c/Dock5 pathway that promotes skin cell proliferation, migration, and adhesion.
New healing pathwayLiraglutide directly binds Myo1c protein to activate wound repair — a completely different mechanism from its blood sugar-lowering action
What the researchers found
Liraglutide directly binds Myo1c at arginine 93, enhances Myo1c/Dock5 interaction to promote keratinocyte proliferation, migration, and adhesion. Dock5 keratinocyte-specific knockout abolished liraglutide wound-healing benefits.
Why it matters
Diabetic foot ulcers lead to over 100,000 amputations per year in the US alone. Liraglutide is already FDA-approved and widely used — discovering that it promotes wound healing through a distinct pathway beyond blood sugar control could immediately expand its clinical applications.
The numbers in context
Liraglutide significantly accelerated wound closure in both db/db and STZ-induced diabetic mouse models.
How the study worked
Wound healing studies in db/db and STZ-induced diabetic mice with liraglutide treatment. Dock5 keratinocyte-specific knockout mice to confirm mechanism. Characterized re-epithelialization, collagen deposition, ECM remodeling, and keratinocyte functions. Identified Myo1c binding site and Dock5 pathway.
Who was studied
db/db and STZ-induced diabetic mice with wound healing models
What this study cannot tell us
Mouse wound models differ from human diabetic ulcers in size, healing dynamics, and microenvironment. The optimal dosing route (systemic vs topical) for wound healing is unclear. Human clinical trials are needed. The mechanism involves a non-GLP-1R pathway, which may behave differently across species.
How to read the evidence
Moderate evidence: published in Advanced Science with thorough mechanistic investigation using knockout mice and two diabetic models, but no human wound healing data yet.
When this study was published
Published in 2024 in Advanced Science. Reveals a novel non-receptor mechanism for GLP-1 drug action.
The bigger picture
GLP-1 drugs continue to reveal unexpected therapeutic effects beyond blood sugar and weight. This study identifies a completely new mechanism — direct protein binding rather than receptor signaling — through which liraglutide promotes tissue repair. If validated in humans, it could transform diabetic wound care and potentially expand to other tissue repair applications.
Questions still open
- Would topical application of liraglutide directly on diabetic wounds be effective, or is systemic dosing required?
- Do patients already taking liraglutide for diabetes show improved wound healing outcomes in clinical records?
- Could this Myo1c/Dock5 pathway be targeted more specifically to develop dedicated wound-healing drugs?
Common questions
Can liraglutide help diabetic wounds heal faster?
How does liraglutide promote wound healing?
Read the original research
Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(39), e2405987
Citation
Zhang, Qian; Zhang, Chunlin; Kang, Changjiang; Zhu, Jiaran; He, Qingshan; Li, Hongwei; Tong, Qiang; Wang, Min; Zhang, Linlin; Xiong, Xin; Wang, Yuren; Qu, Hua; Zheng, Hongting; Zheng, Yi. (2024). Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(39), e2405987. https://doi.org/10.1002/advs.202405987